Skip to content

Global Promise

Insights on International Collaborative Health

Global Promise Home Academic Medicine Voicing a Silent Epidemic

Blood clots cause the world’s top three cardiovascular killers, and they are the leading cause of preventable death during a hospital stay. Altogether, blood clots kill more people each year than AIDS, breast cancer and car crashes combined.

Continuing our discussion on accreditation and uniform health standards in our globalized world, regulatory agencies around the world often take blood clots as signals that safety and quality measures are lacking.

As our global affiliates strive to earn international accreditation—and use that accreditation to become role models for safety in their regions—eliminating blood clots and other avoidable risks for patient harm becomes an important focus.

As we work with health systems worldwide to improve clinical quality, enhance safety efforts and train staff to create a secure environment for care, we often rely on experts and resources from the Johns Hopkins’ Armstrong Institute for Patient Safety and Quality.

Among the Armstrong Institute’s many improvement and research projects is its Venous Thromboembolism Collaborative. The group offers consultation on preventing blood clots by identifying patient risks; sharing relevant research from Johns Hopkins experts; and providing patient education resources, including videos and handouts in multiple languages.

One of those experts, hematologist Michael B. Streiff, traveled to Johns Hopkins Aramco Healthcare last year to present a well-attended public lecture on preventing and treating blood clots, which he calls “a silent epidemic.” He stressed that blood clots are, in fact, a serious medical problem—and can even result in sudden death if they move into a person’s lungs. Streiff also shared information on how to prevent blood clots during hospitalization and everyday life.

Another expert on the effects and avoidance of blood clots, Elliott R. Haut, JHM surgeon and vice chair of quality, safety and service, published research on how regulatory agencies like the Joint Commission International can revise their policies to continue to raise the standards of blood clot prevention. He recommends changing the frequency of administering preventive medications, tracking those dosages closely using electronic medical records, and providing special training for nurses and patients to ensure every dose of prescribed medication is offered and accepted.

Across Johns Hopkins, we conduct this kind of probing, practical research—and share solutions with clinicians, industry leaders, policymakers and patients to reduce suffering and save lives around the world.


Karen Haller

Vice President, Nursing and Clinical Affairs | Vice President, Americas Operations As the vice president of nursing and clinical affairs, Karen Haller oversees nursing and clinical quality for Johns Hopkins Medicine International (JHI). She develops the structure and resources needed to collaborate with health care organizations around the world and supports international patients seeking care at Johns Hopkins medical institutions. She also provides leadership and strategic oversight for JHI’s clinical, consulting and knowledge-transfer activities. Click here to learn more about Karen.

1 thought on “Voicing a Silent Epidemic”

  1. Agree for a "silent epidemic" as a condition but as far as measures it is not "silent" and DVT/PE are core for many publically reported measures and affect reimbursement as well as ranking (US News WR, and Leap Frog grades).

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.